Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Alkyne-tagged PLGA allows direct visualisation of nanoparticles in vitro and ex vivo by stimulated Raman scattering microscopy.

Vanden-Hehir S, Cairns SA, Lee M, Zoupi L, Shaver MP, Brunton VG, Williams A, Hulme AN.

Biomacromolecules. 2019 Aug 13. doi: 10.1021/acs.biomac.9b01092. [Epub ahead of print]

PMID:
31408325
2.

Inhibition of cyclin-dependent kinase activity exacerbates H2 O2 -induced DNA damage in Kindler syndrome keratinocytes.

Emmert H, Culley J, Brunton VG.

Exp Dermatol. 2019 Jul 1. doi: 10.1111/exd.14000. [Epub ahead of print]

PMID:
31260568
3.

Development of mouse models of angiosarcoma driven by p53.

Salter DM, Griffin M, Muir M, Teo K, Culley J, Smith JR, Gomez-Cuadrado L, Matchett K, Sims AH, Hayward L, Henderson NC, Brunton VG.

Dis Model Mech. 2019 Jul 9;12(7). pii: dmm038612. doi: 10.1242/dmm.038612.

4.

The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype.

Hari P, Millar FR, Tarrats N, Birch J, Quintanilla A, Rink CJ, Fernández-Duran I, Muir M, Finch AJ, Brunton VG, Passos JF, Morton JP, Boulter L, Acosta JC.

Sci Adv. 2019 Jun 5;5(6):eaaw0254. doi: 10.1126/sciadv.aaw0254. eCollection 2019 Jun.

5.

Raman Imaging of Nanocarriers for Drug Delivery.

Vanden-Hehir S, Tipping WJ, Lee M, Brunton VG, Williams A, Hulme AN.

Nanomaterials (Basel). 2019 Mar 3;9(3). pii: E341. doi: 10.3390/nano9030341. Review.

6.

Development of a fluorescence-based cellular apoptosis reporter.

Balderstone LA, Dawson JC, Welman A, Serrels A, Wedge SR, Brunton VG.

Methods Appl Fluoresc. 2018 Oct 24;7(1):015001. doi: 10.1088/2050-6120/aae6f8.

7.

E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer.

Teo K, Gómez-Cuadrado L, Tenhagen M, Byron A, Rätze M, van Amersfoort M, Renes J, Strengman E, Mandoli A, Singh AA, Martens JH, Stunnenberg HG, van Diest PJ, Brunton VG, Derksen PWB.

Sci Rep. 2018 Oct 18;8(1):15454. doi: 10.1038/s41598-018-33525-5.

8.

ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells.

Sarvi S, Crispin R, Lu Y, Zeng L, Hurley TD, Houston DR, von Kriegsheim A, Chen CH, Mochly-Rosen D, Ranzani M, Mathers ME, Xu X, Xu W, Adams DJ, Carragher NO, Fujita M, Schuchter L, Unciti-Broceta A, Brunton VG, Patton EE.

Cell Chem Biol. 2018 Dec 20;25(12):1456-1469.e6. doi: 10.1016/j.chembiol.2018.09.005. Epub 2018 Oct 4.

9.

Imaging drug uptake by bioorthogonal stimulated Raman scattering microscopy.

Tipping WJ, Lee M, Serrels A, Brunton VG, Hulme AN.

Chem Sci. 2017 Aug 1;8(8):5606-5615. doi: 10.1039/c7sc01837a. Epub 2017 May 24.

10.

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.

Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaitė Ž, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D.

Nature. 2018 Jul;559(7713):285-289. doi: 10.1038/s41586-018-0291-z. Epub 2018 Jul 4.

11.

Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.

Myers SH, Temps C, Houston DR, Brunton VG, Unciti-Broceta A.

J Med Chem. 2018 Mar 8;61(5):2104-2110. doi: 10.1021/acs.jmedchem.7b01605. Epub 2018 Feb 21.

12.

Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis.

Sarvi S, Patel H, Li J, Dodd GL, Creedon H, Muir M, Ward J, Dawson JC, Lee M, Culley J, Salter DM, Sims AH, Byron A, Brunton VG.

Cancer Res. 2018 Mar 15;78(6):1484-1496. doi: 10.1158/0008-5472.CAN-17-1518. Epub 2018 Jan 12.

13.

Mouse models of metastasis: progress and prospects.

Gómez-Cuadrado L, Tracey N, Ma R, Qian B, Brunton VG.

Dis Model Mech. 2017 Sep 1;10(9):1061-1074. doi: 10.1242/dmm.030403. Review.

14.

Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.

Canel M, Byron A, Sims AH, Cartier J, Patel H, Frame MC, Brunton VG, Serrels B, Serrels A.

Cancer Res. 2017 Oct 1;77(19):5301-5312. doi: 10.1158/0008-5472.CAN-17-0418. Epub 2017 Aug 14.

15.

Kindlin-1 protects cells from oxidative damage through activation of ERK signalling.

Emmert H, Patel H, Brunton VG.

Free Radic Biol Med. 2017 Jul;108:896-903. doi: 10.1016/j.freeradbiomed.2017.05.013. Epub 2017 May 10.

PMID:
28501563
16.

The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer.

Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T.

Nat Cell Biol. 2017 May;19(5):518-529. doi: 10.1038/ncb3513. Epub 2017 Apr 17.

PMID:
28414315
17.

WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel.

Artibani M, Sims AH, Slight J, Aitken S, Thornburn A, Muir M, Brunton VG, Del-Pozo J, Morrison LR, Katz E, Hastie ND, Hohenstein P.

Sci Rep. 2017 Mar 27;7:45255. doi: 10.1038/srep45255.

18.

Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.

Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, Muir M, Harrington L, Webster SP, Frame MC, Brunton VG, Patton EE, Carragher NO, Unciti-Broceta A.

J Med Chem. 2016 May 26;59(10):4697-710. doi: 10.1021/acs.jmedchem.6b00065. Epub 2016 May 4.

19.

Kindlin1 regulates microtubule function to ensure normal mitosis.

Patel H, Stavrou I, Shrestha RL, Draviam V, Frame MC, Brunton VG.

J Mol Cell Biol. 2016 Aug;8(4):338-48. doi: 10.1093/jmcb/mjw009. Epub 2016 Mar 18.

20.

Integrin signalling regulates YAP and TAZ to control skin homeostasis.

Elbediwy A, Vincent-Mistiaen ZI, Spencer-Dene B, Stone RK, Boeing S, Wculek SK, Cordero J, Tan EH, Ridgway R, Brunton VG, Sahai E, Gerhardt H, Behrens A, Malanchi I, Sansom OJ, Thompson BJ.

Development. 2016 May 15;143(10):1674-87. doi: 10.1242/dev.133728. Epub 2016 Mar 17.

21.

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.

Creedon H, Gómez-Cuadrado L, Tarnauskaitė Ž, Balla J, Canel M, MacLeod KG, Serrels B, Fraser C, Unciti-Broceta A, Tracey N, Le Bihan T, Klinowska T, Sims AH, Byron A, Brunton VG.

Oncotarget. 2016 Mar 8;7(10):11539-52. doi: 10.18632/oncotarget.7317.

22.

Stimulated Raman scattering microscopy: an emerging tool for drug discovery.

Tipping WJ, Lee M, Serrels A, Brunton VG, Hulme AN.

Chem Soc Rev. 2016 Apr 21;45(8):2075-89. doi: 10.1039/c5cs00693g. Epub 2016 Feb 3. Review.

23.

Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.

Creedon H, Balderstone LA, Muir M, Balla J, Gomez-Cuadrado L, Tracey N, Loane J, Klinowska T, Muller WJ, Brunton VG.

Dis Model Mech. 2016 Feb;9(2):131-40. doi: 10.1242/dmm.023143. Epub 2015 Dec 31.

24.

ADF and Cofilin1 Control Actin Stress Fibers, Nuclear Integrity, and Cell Survival.

Kanellos G, Zhou J, Patel H, Ridgway RA, Huels D, Gurniak CB, Sandilands E, Carragher NO, Sansom OJ, Witke W, Brunton VG, Frame MC.

Cell Rep. 2015 Dec 1;13(9):1949-64. doi: 10.1016/j.celrep.2015.10.056. Epub 2015 Nov 19.

25.

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.

Myers SH, Brunton VG, Unciti-Broceta A.

J Med Chem. 2016 Apr 28;59(8):3593-608. doi: 10.1021/acs.jmedchem.5b01273. Epub 2015 Nov 20. Review.

26.

Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.

Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC.

Cell. 2015 Sep 24;163(1):160-73. doi: 10.1016/j.cell.2015.09.001.

27.

The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.

Teo K, Brunton VG.

Biochem J. 2014 Oct 1;463(1):157-65. doi: 10.1042/BJ20140680. Review.

PMID:
25195735
28.

N-alkynyl derivatives of 5-fluorouracil: susceptibility to palladium-mediated dealkylation and toxigenicity in cancer cell culture.

Weiss JT, Fraser C, Rubio-Ruiz B, Myers SH, Crispin R, Dawson JC, Brunton VG, Patton EE, Carragher NO, Unciti-Broceta A.

Front Chem. 2014 Jul 29;2:56. doi: 10.3389/fchem.2014.00056. eCollection 2014.

29.

Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.

Creedon H, Byron A, Main J, Hayward L, Klinowska T, Brunton VG.

Biochem Soc Trans. 2014 Aug;42(4):822-30. doi: 10.1042/BST20140109. Review.

PMID:
25109964
30.

Cell biology. Where is PTEN?

Leslie NR, Brunton VG.

Science. 2013 Jul 26;341(6144):355-6. doi: 10.1126/science.1242541. No abstract available.

PMID:
23888029
31.

Kindlin-1 regulates mitotic spindle formation by interacting with integrins and Plk-1.

Patel H, Zich J, Serrels B, Rickman C, Hardwick KG, Frame MC, Brunton VG.

Nat Commun. 2013;4:2056. doi: 10.1038/ncomms3056.

PMID:
23804033
32.

Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer.

Nobis M, McGhee EJ, Morton JP, Schwarz JP, Karim SA, Quinn J, Edward M, Campbell AD, McGarry LC, Evans TR, Brunton VG, Frame MC, Carragher NO, Wang Y, Sansom OJ, Timpson P, Anderson KI.

Cancer Res. 2013 Aug 1;73(15):4674-86. doi: 10.1158/0008-5472.CAN-12-4545. Epub 2013 Jun 7.

33.

Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.

Karim SA, Creedon H, Patel H, Carragher NO, Morton JP, Muller WJ, Evans TR, Gusterson B, Sansom OJ, Brunton VG.

J Pathol. 2013 Aug;230(4):430-40. doi: 10.1002/path.4202.

PMID:
23616343
34.

QD-filled micelles which combine SPECT and optical imaging with light-induced activation of a platinum(IV) prodrug for anticancer applications.

Maldonado CR, Gómez-Blanco N, Jauregui-Osoro M, Brunton VG, Yate L, Mareque-Rivas JC.

Chem Commun (Camb). 2013 May 11;49(38):3985-7. doi: 10.1039/c3cc39104c. Epub 2013 Apr 4.

PMID:
23552819
35.

E-cadherin-integrin crosstalk in cancer invasion and metastasis.

Canel M, Serrels A, Frame MC, Brunton VG.

J Cell Sci. 2013 Jan 15;126(Pt 2):393-401. doi: 10.1242/jcs.100115. Epub 2013 Mar 22. Review.

36.

Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.

Logan JG, Sophocleous A, Marino S, Muir M, Brunton VG, Idris AI.

J Bone Miner Res. 2013 May;28(5):1229-42. doi: 10.1002/jbmr.1847.

37.

Focal adhesion kinase is required for β-catenin-induced mobilization of epidermal stem cells.

Ridgway RA, Serrels B, Mason S, Kinnaird A, Muir M, Patel H, Muller WJ, Sansom OJ, Brunton VG.

Carcinogenesis. 2012 Dec;33(12):2369-76. doi: 10.1093/carcin/bgs284. Epub 2012 Sep 12.

PMID:
22971575
38.

Diversity of matriptase expression level and function in breast cancer.

Welman A, Sproul D, Mullen P, Muir M, Kinnaird AR, Harrison DJ, Faratian D, Brunton VG, Frame MC.

PLoS One. 2012;7(4):e34182. doi: 10.1371/journal.pone.0034182. Epub 2012 Apr 13.

39.

Combining imaging and pathway profiling: an alternative approach to cancer drug discovery.

Carragher NO, Brunton VG, Frame MC.

Drug Discov Today. 2012 Mar;17(5-6):203-14. Review.

PMID:
22493783
40.

Src kinase inhibitors: promising cancer therapeutics?

Creedon H, Brunton VG.

Crit Rev Oncog. 2012;17(2):145-59. Review.

PMID:
22471705
41.

FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells.

Graham K, Moran-Jones K, Sansom OJ, Brunton VG, Frame MC.

PLoS One. 2011;6(12):e27806. doi: 10.1371/journal.pone.0027806. Epub 2011 Dec 14.

42.

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL.

Blood. 2012 Feb 9;119(6):1501-10. doi: 10.1182/blood-2010-12-326843. Epub 2011 Dec 19.

43.

Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling.

Sandilands E, Serrels B, McEwan DG, Morton JP, Macagno JP, McLeod K, Stevens C, Brunton VG, Langdon WY, Vidal M, Sansom OJ, Dikic I, Wilkinson S, Frame MC.

Nat Cell Biol. 2011 Dec 4;14(1):51-60. doi: 10.1038/ncb2386.

PMID:
22138575
44.

HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.

Ahmad I, Patel R, Singh LB, Nixon C, Seywright M, Barnetson RJ, Brunton VG, Muller WJ, Edwards J, Sansom OJ, Leung HY.

Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16392-7. doi: 10.1073/pnas.1101263108. Epub 2011 Sep 19.

45.

Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging.

Serrels A, Canel M, Brunton VG, Frame MC.

Cell Adh Migr. 2011 Jul-Aug;5(4):360-5. Epub 2011 Jul 1. Review.

46.

The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.

Serrels A, McLeod K, Canel M, Kinnaird A, Graham K, Frame MC, Brunton VG.

Int J Cancer. 2012 Jul 15;131(2):287-97. doi: 10.1002/ijc.26351. Epub 2011 Aug 30.

47.

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion.

Glen H, Mason S, Patel H, Macleod K, Brunton VG.

BMC Cancer. 2011 Jul 22;11:309. doi: 10.1186/1471-2407-11-309.

48.

Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth.

Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, Munro J, Schröder E, Zhou J, Brunton VG, Barker N, Clevers H, Sansom OJ, Anderson KI, Weaver VM, Olson MF.

Cancer Cell. 2011 Jun 14;19(6):776-91. doi: 10.1016/j.ccr.2011.05.008.

49.

Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.

Timpson P, McGhee EJ, Morton JP, von Kriegsheim A, Schwarz JP, Karim SA, Doyle B, Quinn JA, Carragher NO, Edward M, Olson MF, Frame MC, Brunton VG, Sansom OJ, Anderson KI.

Cancer Res. 2011 Feb 1;71(3):747-57. doi: 10.1158/0008-5472.CAN-10-2267. Epub 2011 Jan 25.

50.

Live cell in vitro and in vivo imaging applications: accelerating drug discovery.

Isherwood B, Timpson P, McGhee EJ, Anderson KI, Canel M, Serrels A, Brunton VG, Carragher NO.

Pharmaceutics. 2011 Apr 4;3(2):141-70. doi: 10.3390/pharmaceutics3020141.

Supplemental Content

Loading ...
Support Center